BioNTech SEBNTXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
BNTX Q3 FY2025 Key Financial Metrics
Revenue
$1.5B
Gross Profit
$1.5B
Operating Profit
$-46.9M
Net Profit
$-28.7M
Gross Margin
99.7%
Operating Margin
-3.1%
Net Margin
-1.9%
YoY Growth
N/A
BioNTech SE Q3 FY2025 Financial Summary
BioNTech SE reported revenue of $1.5B for Q3 FY2025, with a net profit of $-28.7M (-1.9% margin).
Key Financial Metrics
| Total Revenue | $1.5B |
|---|---|
| Net Profit | $-28.7M |
| Gross Margin | N/A |
| Operating Margin | -3.1% |
| Report Period | Q3 FY2025 |
BioNTech SE Quarterly Revenue & Net Profit History
BioNTech SE results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $1.5B | — | $-28.7M | -1.9% |
| Q2 FY2025 | $260.8M | — | $-386.6M | -148.2% |
| Q3 FY2024 | $1.2B | — | $198.1M | 15.9% |
Income Statement
| Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $1.24B | $260.8M | $1.52B |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | N/A | N/A | N/A |
| Liabilities | N/A | N/A | N/A |
| Equity | N/A | N/A | N/A |
Cash Flow
No data available for this period